Anyone considering the use of Strattera in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be monitored closely for suicidality suicidal thinking and behaviorclinical worsening, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.
During the clinical studies, adult patients were treated for at least 6 months. Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories.
In the tables and listings that follow, MedDRA terminology has been used to classify reported adverse events. The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed.
An event was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. None of the 53 Focalin XR-treated pediatric patients discontinued treatment due to adverse events in the 7-week, placebo-controlled study.
The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials.
Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the adverse event incidence rate in the population studied.By Tammy Preston, MS.
Generic Name: Bupropion (bew-PROH-pee-on) Brand Names: Wellbutrin®, Zyban®, Budeprion®, Aplenzin®, Voxra® Manufacturers: GlaxoSmithKline Inc.
What is Wellbutrin®? Wellbutrin® is an antidepressant that has shown promise in helping people with childhood and adult ADHD.
76 rows · timberdesignmag.com provides accurate and independent information on more than 24, . ADHD medications do indeed have side effects; however, the advantages of treatment generally outweigh the disadvantages of negative side effects.
This can be seen by examining the symptoms associated with ADHD, and comparing them to the side effects of stimulant medication. Vyvanse is used for the treatment of attention deficit hyperactivity disorder (ADHD), and moderate to severe binge eating disorder. Adderall is used for the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy.
Adderall XR is only approved for treatment of ADHD.
This guide to the scientific literature on withdrawal from ADHD drugs provides a review of animal studies, withdrawal syndromes, and possible tapering protocols. Concerta ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see Clinical Studies (14)]..
A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before.